Principles of iron therapy in hemodialysis patients;Liječenje željezom bolesnika na hemodijalizi

Acta Medica Croatica

Volumn 60, Issue 5, 2006, Pages 457-462

  Bašić Jukić, Nikolina ^a,b   Kes, Petar ^a,b   Jurić, Ivana ^a,b  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Anemia; Chronic renal failure; Hemodialysis; Iron; Side effects

Indexed keywords

ERYTHROPOIETIN; IRON; IRON DEXTRAN; IRON DERIVATIVE;

ANAPHYLAXIS; ANEMIA; BLEEDING; DISEASE ASSOCIATION; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HUMAN; INFECTION RISK; IRON THERAPY; KIDNEY DISEASE; KIDNEY FAILURE; LONG TERM CARE; MORBIDITY; MORTALITY; OXIDATIVE STRESS; REVIEW; CHRONIC KIDNEY FAILURE; IRON DEFICIENCY ANEMIA; METABOLISM; RENAL REPLACEMENT THERAPY;

ANEMIA, IRON-DEFICIENCY; HUMANS; IRON COMPOUNDS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 33846037180     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Horl WH, Dreyling K, Steinhauer HB i sur. Iron status of dialysis patients under rhuEPO therapy. Contrib Nephrol 1990; 87: 78-85.
2. Fishbane S, Kowalski EA, Imbriano Lj, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996; 7: 2654-9.
3. Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three diferent iron treatments. Nephron 1991; 57: 175-81.
4. Jacobs A, Worwood M. Ferritin in serum: clinical and biochemical implications. N Engl J Med 1975; 292: 951-7.
5. Eshbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977; 87: 710-6.
6. Fishbane S, Lynn RI. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 1995; 25: 426-32.
7. Schaefer RM, Schaefer L. The hypochromic red cell: a new parameter for monitoring iron supplementation during rhEPO therapy. J Perinat Med 1995; 23: 83-7.
8. Milman N. Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. Clin Nephrol 1982; 17: 77-81.
9. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995; 25: 433-9.
10. Johnson CA, Rosowski E, Zimmerman SW. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN. Adv Pent Dial 1992; 8: 444-8.
11. Piraio-Biroli G, Both well TH, Finch CA. Iron absorption. II. The absorption of radioion administered with a standard meal in men. J Lab Clin Med 1958; 9: 24-34.
12. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999; 34: 21-6.
13. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF K/DOQI). Guidelines for anemia of chronic kidney disease. Dostupan na adresi: www.kidney.org/professionals/kdoqi/guidelines/doqiupan_ii.html
14. Locatelli F, Aljama P, Barany P i sur. European best practice guidelines II: Targets for anaemia treatment. Nephrol Dial Transplant 2004; 19(Suppl 2): ii6-ii15.
15. Aronoff GR. Safety of intravenous iron in clinical practice: Implications for anemia management protocols. J Am Soc Nephrol 2004; 15 (Suppl 2): S99-S106.
16. Van Wyck DB, Cavallo G, Spinowitz BS i sur. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000; 36: 88-97.
17. Fishbane S, Ungureanu VD, Maesaka JK i sur. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-34.
18. Hamstra RD, Block MH, Shocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-31.
19. Pascual J, Teruel JL, Liano F i sur. Serious adverse reactions after intravenous ferric gluconate. Nephrol Dial Transplant 1992; 7: 271-5.
20. Bašić-Jukić N, Brunetta B, Blažev M, Blajić I, Dumančić N, Kes P. Erythrocytosis in a hemodialysis patient treated with iron-sucrose. Acta Clin Croat 2004; 43: 385-8.
21. Anastassiades EG, Howarth D, Howarth J i sur. Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 1993; 8: 846-50.
22. Gokal R, Millard PR, Weatherall DJ i sur. Iron metabolism in haemodialysis patients: a study of the management of iron therapy and overload. Q J Med 1979; 48: 369-74.
23. Kalantar-Zadeh K, Hoffken B, Wunsch H i sur. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26: 292-8.
24. Seifert A, von Herrath D, Schaeffer K. Iron overload, but not treatment with desferrioxamine favours the development of septicaemia in patients on maintenance haemodialysis. Q J Med 1987; 65: 1015-24.
25. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995; 10: 377-81.
26. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-76.
27. Boelaert JR, Daneels RF, Schurgers ML i sur. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990; 5: 130-4.
28. Patruta SI, Horl WH. Iron and infection. Kidney Int 1999; 55(Suppl 69): S125-30.
29. Hatton RC, Portales IT, Finlay A, Ross EA. Removal of iron dextran by hemodialysis: an in vitro study. Am J Kidney Dis 1995; 26: 327-30.
30. Manuel MA, Stewart WK, Clair Neill GD, Hutchinson F. Loss of iron-dextran through cuprophane membrane of a disposable coil dialyser. Nephron 1972; 9: 94-8.
31. Calvar C, Mata D, Alonso C, Ramos B, Lopez DN. Intravenous administration of iron gluconate during haemodialysis. Nephrol Dial Transplant 1997; 12: 574-5.
32. Kooistra MP, Kersting G, Gosriwatana I, Lu S, Nijhoff-Schutte J, Hider RC. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002; 32(Suppl1): 36-41.
33. Van Wyck DB. Labile iron: manifestations and clinical implications. J Am Soc Nephrol 2004; 15: 107-11.
34. Cavill I. Intravenous iron as adjuvant therapy: a two-edged sword? Nephrol Dial Transplant 2003; 18(Suppl 8): 24-8.
35. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: A quantitative and comparative study. Nephrol Dial Transplant 2004; 19: 561-5.
36. Cavill I, Fisher J. Non-transferin-bound iron: an apparent artefact. Clin Lab Haem 2003; 49: 279-38.
37. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103.
38. Zager RA, Johnson ACM, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 2004; 65: 2108-12.
39. Deicher R, Ziai F, Cohen G i sur. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003; 64: 728-36.
40. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 2004; 65: 1802-9.
41. Roob JM, Khoschsorur G, Tiran A i sur. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11: 539-49.
42. Salahudeen AK, Oliver B, Bower JD, Roberts II LJ. Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001; 60: 1525-31.
43. Michelis R, Gery R, Sela S i sur. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003; 18: 924-30.
44. Drueke T, Witko-Sarsat V, Massy Z i sur. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-7.
45. Feldman HI, Santanna J, Guo W i sur. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13: 734-44.
46. Feldman HI, Joffe M, Robinson B i sur. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-32.
47. Kalantar-Zadeh Regidor DL, McAllister CJ, Michael B i sur. Time-dependent associations between indices of iron store and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-80.